BRPI1008793A2 - composto, uso de um composto, e, composição farmacêutica - Google Patents
composto, uso de um composto, e, composição farmacêuticaInfo
- Publication number
- BRPI1008793A2 BRPI1008793A2 BRPI1008793A BRPI1008793A BRPI1008793A2 BR PI1008793 A2 BRPI1008793 A2 BR PI1008793A2 BR PI1008793 A BRPI1008793 A BR PI1008793A BR PI1008793 A BRPI1008793 A BR PI1008793A BR PI1008793 A2 BRPI1008793 A2 BR PI1008793A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- compound use
- pharmaceutical
- composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20864809P | 2009-02-26 | 2009-02-26 | |
| PCT/US2010/024853 WO2010099054A2 (en) | 2009-02-26 | 2010-02-22 | Soluble guanylate cyclase activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1008793A2 true BRPI1008793A2 (pt) | 2016-03-08 |
Family
ID=42410011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1008793A BRPI1008793A2 (pt) | 2009-02-26 | 2010-02-22 | composto, uso de um composto, e, composição farmacêutica |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8507512B2 (pt) |
| EP (1) | EP2401265B1 (pt) |
| JP (1) | JP5411300B2 (pt) |
| KR (1) | KR20110133034A (pt) |
| CN (1) | CN102414194A (pt) |
| AR (1) | AR075609A1 (pt) |
| AU (1) | AU2010218224B2 (pt) |
| BR (1) | BRPI1008793A2 (pt) |
| CA (1) | CA2753434C (pt) |
| CO (1) | CO6430463A2 (pt) |
| IL (1) | IL214559A0 (pt) |
| MX (1) | MX2011008952A (pt) |
| RU (1) | RU2011138970A (pt) |
| TW (1) | TW201035077A (pt) |
| WO (1) | WO2010099054A2 (pt) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101939053A (zh) * | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| CA2753434C (en) | 2009-02-26 | 2014-07-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| GB2486631A (en) * | 2010-12-01 | 2012-06-27 | Univ Sheffield | Phenol/quinone boronic acids/esters and method of preparation thereof |
| US8569339B2 (en) | 2011-03-10 | 2013-10-29 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| WO2013025425A1 (en) | 2011-08-12 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
| WO2013192125A1 (en) * | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
| MX338887B (es) | 2012-09-07 | 2016-05-04 | Boehringer Ingelheim Int | Alcoxipirazoles como activadores de guanilato ciclasa soluble. |
| ES2911276T3 (es) | 2013-03-15 | 2022-05-18 | Cyclerion Therapeutics Inc | Estimuladores de sGC |
| RU2016112542A (ru) * | 2013-09-05 | 2017-10-06 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Новые активаторы растворимой гуанилатциклазы и их применение |
| WO2015088885A1 (en) | 2013-12-11 | 2015-06-18 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP3079700B1 (en) | 2013-12-11 | 2020-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| JP2016540017A (ja) | 2013-12-11 | 2016-12-22 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | sGC刺激物質 |
| WO2015095515A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
| WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| US9796733B2 (en) | 2014-06-04 | 2017-10-24 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
| TW201625586A (zh) * | 2014-07-02 | 2016-07-16 | 諾華公司 | 環己烯-1-基-吡啶-2-基-1h-吡唑-4-羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| TW201625601A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 噻吩-2-基-吡啶-2-基-1h-吡唑-4-羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| TW201625584A (zh) * | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| AU2015292833B2 (en) | 2014-07-22 | 2019-11-28 | Boehringer Ingelheim International Gmbh | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase |
| CN105980373A (zh) * | 2014-09-05 | 2016-09-28 | 葛兰素史密斯克莱知识产权发展有限公司 | 新的可溶性鸟苷酸环化酶活化剂及它们的用途 |
| WO2016044445A2 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| US10844064B2 (en) | 2014-09-17 | 2020-11-24 | Cyclerion Therapeutics, Inc. | sGC stimulators |
| EP3194382B1 (en) | 2014-09-17 | 2021-09-08 | Cyclerion Therapeutics, Inc. | Pyrazole derivatives as sgc stimulators |
| EA033697B1 (ru) | 2014-09-19 | 2019-11-18 | Glaxosmithkline Ip Dev Ltd | Активаторы растворимой гуанилатциклазы и их применение |
| TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
| US10245264B2 (en) | 2015-05-27 | 2019-04-02 | Merck Sharp & Dohme Corp. | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators |
| EP3310782B1 (en) | 2015-05-28 | 2021-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
| LT3307739T (lt) | 2015-06-15 | 2021-03-10 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 reguliatoriai |
| AU2016280236B2 (en) | 2015-06-15 | 2019-02-07 | Astex Therapeutics Limited | Nrf2 regulators |
| US10351530B2 (en) * | 2015-10-06 | 2019-07-16 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as NRF2 regulators |
| US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
| KR20180094965A (ko) | 2015-12-14 | 2018-08-24 | 아이언우드 파마슈티컬스, 인코포레이티드 | 위장 괄약근 기능장애의 치료를 위한 sGC 자극제의 용도 |
| CN108473470A (zh) * | 2015-12-18 | 2018-08-31 | 诺华股份有限公司 | 作为可溶性鸟苷酸环化酶激活剂的茚满衍生物及其用途 |
| WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
| WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
| US10925876B2 (en) | 2016-05-18 | 2021-02-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
| KR102513343B1 (ko) | 2016-07-07 | 2023-03-22 | 사이클리온 테라퓨틱스, 인크. | sGC 자극제의 인 전구약물 |
| EA039753B1 (ru) | 2016-07-07 | 2022-03-10 | Сайклерион Терапьютикс, Инк. | ТВЕРДЫЕ ФОРМЫ СТИМУЛЯТОРА sGC |
| IL264955B (en) | 2016-09-02 | 2022-06-01 | Ironwood Pharmaceuticals Inc | Fused bicyclic sgc stimulators |
| US11331308B2 (en) | 2016-10-11 | 2022-05-17 | Bayer Pharma Aktiengesellschaft | Combination containing sGC activators and mineralocorticoid receptor antagonists |
| AU2017356887B2 (en) | 2016-11-08 | 2022-06-30 | Cyclerion Therapeutics, Inc. | sGC stimulators |
| EP3538096B1 (en) | 2016-11-08 | 2024-02-28 | Tisento Therapeutics Inc. | Treatment of cns diseases with sgc stimulators |
| WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
| WO2019055859A1 (en) * | 2017-09-14 | 2019-03-21 | Ironwood Pharmaceuticals, Inc. | TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| JP7337067B2 (ja) | 2017-12-19 | 2023-09-01 | サイクレリオン・セラピューティクス,インコーポレーテッド | sGC刺激薬 |
| CN111836812A (zh) | 2018-03-07 | 2020-10-27 | 塞科里昂医疗股份有限公司 | sGC刺激剂的晶型 |
| CN112055584A (zh) | 2018-04-30 | 2020-12-08 | 拜耳公司 | sGC活化剂和sGC刺激剂用于治疗认知障碍的用途 |
| MA52616A (fr) | 2018-05-15 | 2021-03-24 | Bayer Ag | Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| US12220414B2 (en) | 2018-07-11 | 2025-02-11 | Tisento Therapeutics Inc. | Use of sGC stimulators for the treatment of mitochondrial disorders |
| EP3887376A1 (en) | 2018-11-28 | 2021-10-06 | Topadur Pharma AG | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
| WO2020148379A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| US20230130739A1 (en) | 2020-03-26 | 2023-04-27 | Cyclerion Therapeutics, Inc. | DEUTERATED sGC STIMULATORS |
| WO2021202546A1 (en) | 2020-03-31 | 2021-10-07 | Cyclerion Therapeutics, Inc. | Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death |
| WO2021245192A1 (en) | 2020-06-04 | 2021-12-09 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
| EP4011873A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| WO2022225902A1 (en) | 2021-04-20 | 2022-10-27 | Cyclerion Therapeutics, Inc. | Treatment of cns diseases with sgc stimulators |
| MX2023012398A (es) | 2021-04-20 | 2024-03-13 | Tisento Therapeutics Inc | Estimuladores de guanilil ciclasa soluble (sgc). |
| WO2022265984A1 (en) | 2021-06-14 | 2022-12-22 | Curtails Llc | Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders |
| WO2023018795A1 (en) | 2021-08-11 | 2023-02-16 | Curtails Llc | Nep inhibitors for the treatment of laminitis |
| CN119300815A (zh) | 2022-06-09 | 2025-01-10 | 拜耳公司 | 用于治疗女性射血分数保留型心力衰竭的可溶性鸟苷酸环化酶激活剂 |
| EP4605394A1 (en) | 2022-10-18 | 2025-08-27 | Tisento Therapeutics Inc. | Pyrimidine sgc stimulators |
| EP4605080A1 (en) | 2022-10-18 | 2025-08-27 | Tisento Therapeutics Inc. | Treatment of mitochondrial diseases with sgc stimulators |
| KR20250088783A (ko) | 2022-11-04 | 2025-06-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 전신 경화증을 치료하기 위한 가용성 구아닐레이트 사이클라제 활성제 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB876526A (en) | 1957-12-24 | 1961-09-06 | Geigy Ag J R | Process for the production of new aminobenzoic acid derivatives and their use in pest control |
| US4845079A (en) | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
| US5066643A (en) | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
| US4894437A (en) | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
| US4885292A (en) | 1986-02-03 | 1989-12-05 | E. R. Squibb & Sons, Inc. | N-heterocyclic alcohol renin inhibitors |
| US4980283A (en) | 1987-10-01 | 1990-12-25 | Merck & Co., Inc. | Renin-inhibitory pepstatin phenyl derivatives |
| US5089471A (en) | 1987-10-01 | 1992-02-18 | G. D. Searle & Co. | Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents |
| US5034512A (en) | 1987-10-22 | 1991-07-23 | Warner-Lambert Company | Branched backbone renin inhibitors |
| US5063207A (en) | 1987-10-26 | 1991-11-05 | Warner-Lambert Company | Renin inhibitors, method for using them, and compositions containing them |
| US5055466A (en) | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
| US5036054A (en) | 1988-02-11 | 1991-07-30 | Warner-Lambert Company | Renin inhibitors containing alpha-heteroatom amino acids |
| US5036053A (en) | 1988-05-27 | 1991-07-30 | Warner-Lambert Company | Diol-containing renin inhibitors |
| DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| US5106835A (en) | 1988-12-27 | 1992-04-21 | American Cyanamid Company | Renin inhibitors |
| US5063208A (en) | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
| US5098924A (en) | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
| US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
| US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
| US5064965A (en) | 1990-03-08 | 1991-11-12 | American Home Products Corporation | Renin inhibitors |
| US5075451A (en) | 1990-03-08 | 1991-12-24 | American Home Products Corporation | Pyrrolimidazolones useful as renin inhibitors |
| US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
| DE4011361A1 (de) | 1990-04-07 | 1991-10-10 | Bayer Ag | 2-aryl-6-hetarylpyridin-derivate |
| US5071837A (en) | 1990-11-28 | 1991-12-10 | Warner-Lambert Company | Novel renin inhibiting peptides |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE19744027A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln |
| GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| US20010044445A1 (en) * | 1999-04-08 | 2001-11-22 | Bamaung Nwe Y. | Azole inhibitors of cytokine production |
| DE19943636A1 (de) * | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| SK11422003A3 (sk) | 2001-03-15 | 2004-04-06 | Basf Aktiengesellschaft | 5-Fenylpyrimidíny, spôsoby a medziprodukty na ich prípravu a ich použitie pri ničení škodlivých húb |
| DE10149370A1 (de) | 2001-10-06 | 2003-04-10 | Merck Patent Gmbh | Pyrazolderivate |
| AU2003294275A1 (en) | 2002-11-21 | 2004-06-18 | New York Blood Center | Compounds for inhibition of hiv infection by blocking hiv entry |
| CA2520804A1 (en) | 2003-04-03 | 2004-10-28 | Merck & Co., Inc. | Biaryl substituted pyrazoles as sodium channel blockers |
| WO2006012181A1 (en) * | 2004-06-24 | 2006-02-02 | Ksn Energies, Llc | Electrical impedance tomography to characterize tissue |
| US7923573B2 (en) | 2004-10-27 | 2011-04-12 | Daiichi Sankyo Company, Limited | Benzene compound having 2 or more substituents |
| EP1846106B1 (en) * | 2005-01-31 | 2012-10-24 | Dong Wha Pharm. Co., Ltd. | Pharmaceutical composition for treating nephropathy and healthy food comprising herb extracts |
| EP1893581B1 (en) | 2005-06-15 | 2010-01-27 | Pfizer Limited | Substituted arylpyrazoles for use against parasitites |
| WO2006134459A1 (en) | 2005-06-15 | 2006-12-21 | Pfizer Limited | Substituted arylpyrazoles |
| KR101363278B1 (ko) * | 2005-06-27 | 2014-02-21 | 엑셀리시스 페이턴트 컴퍼니 엘엘씨 | 이미다졸계 lxr 변조제 |
| DE102005050375A1 (de) * | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Tetrazol-Derivate und ihre Verwendung |
| WO2008045484A1 (en) | 2006-10-10 | 2008-04-17 | Amgen Inc. | N-aryl pyrazole compounds for use against diabetes |
| DE102007015035A1 (de) * | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Substituierte Dibenzoesäure-Derivate und ihre Verwendung |
| DE102007015034A1 (de) * | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Lactam-substituierte Dicarbonsäuren und ihre Verwendung |
| CN101939053A (zh) * | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| WO2009068652A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
| PE20091258A1 (es) | 2007-12-03 | 2009-09-12 | Smithkline Beecham Corp | Derivados de piridina como activadores de la guanilato ciclasa soluble |
| CN102056907B (zh) | 2008-04-04 | 2014-12-31 | 武田药品工业株式会社 | 杂环衍生物及其用途 |
| WO2010015652A2 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Thiazole compounds as activators of soluble guanylate cyclase |
| WO2010015653A1 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
| CA2753434C (en) | 2009-02-26 | 2014-07-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
-
2010
- 2010-02-22 CA CA2753434A patent/CA2753434C/en not_active Expired - Fee Related
- 2010-02-22 JP JP2011552075A patent/JP5411300B2/ja not_active Expired - Fee Related
- 2010-02-22 BR BRPI1008793A patent/BRPI1008793A2/pt not_active IP Right Cessation
- 2010-02-22 WO PCT/US2010/024853 patent/WO2010099054A2/en not_active Ceased
- 2010-02-22 AU AU2010218224A patent/AU2010218224B2/en not_active Ceased
- 2010-02-22 RU RU2011138970/04A patent/RU2011138970A/ru not_active Application Discontinuation
- 2010-02-22 MX MX2011008952A patent/MX2011008952A/es active IP Right Grant
- 2010-02-22 CN CN2010800184490A patent/CN102414194A/zh active Pending
- 2010-02-22 KR KR1020117022295A patent/KR20110133034A/ko not_active Ceased
- 2010-02-22 EP EP10705728.3A patent/EP2401265B1/en active Active
- 2010-02-24 US US12/711,854 patent/US8507512B2/en active Active
- 2010-02-25 TW TW099105497A patent/TW201035077A/zh unknown
- 2010-02-25 AR ARP100100555A patent/AR075609A1/es not_active Application Discontinuation
-
2011
- 2011-08-09 IL IL214559A patent/IL214559A0/en unknown
- 2011-09-12 CO CO11117858A patent/CO6430463A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR075609A1 (es) | 2011-04-20 |
| RU2011138970A (ru) | 2013-04-10 |
| AU2010218224B2 (en) | 2013-06-27 |
| US8507512B2 (en) | 2013-08-13 |
| KR20110133034A (ko) | 2011-12-09 |
| JP2012519169A (ja) | 2012-08-23 |
| WO2010099054A3 (en) | 2010-10-21 |
| JP5411300B2 (ja) | 2014-02-12 |
| TW201035077A (en) | 2010-10-01 |
| US20100216764A1 (en) | 2010-08-26 |
| WO2010099054A2 (en) | 2010-09-02 |
| CA2753434C (en) | 2014-07-15 |
| EP2401265B1 (en) | 2016-09-14 |
| CA2753434A1 (en) | 2010-09-02 |
| MX2011008952A (es) | 2011-09-27 |
| AU2010218224A1 (en) | 2011-09-08 |
| CN102414194A (zh) | 2012-04-11 |
| EP2401265A2 (en) | 2012-01-04 |
| IL214559A0 (en) | 2011-09-27 |
| CO6430463A2 (es) | 2012-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1016219A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0919942A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BRPI0907562A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0921375A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI1007018A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
| BR112013008259A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI1008906A2 (pt) | composto, composição farmacêutica, e, uso de um composto. | |
| BR112013015397A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0917579A2 (pt) | composto, composição farmacêutica, métodos, e, uso de um composto | |
| BRPI0921879A2 (pt) | composto, composição farmacêutica , e, uso de um composto | |
| BRPI0810696A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BR112014001255A2 (pt) | composto, uso de um composto, combinação, e, composição farmacêutica | |
| BRPI0810161A2 (pt) | Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto | |
| BR112014013760A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BRPI0918360A2 (pt) | composto, composição farmacêutica e usos de um composto | |
| BRPI1009757A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
| BRPI0906937A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112014005669A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112014003567A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| BRPI0915134A2 (pt) | composto, e, uso de um composto | |
| BRPI1007186A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0812942A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
| BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica | |
| BRPI0915473A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0810019A2 (pt) | Composto, composição farmacêutica, e, uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADES |
|
| B25A | Requested transfer of rights approved |
Owner name: SCHERING CORPORATION (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2369 DE 31-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |